Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy (Q28235507)

2

0 references

Athanassios Lourbopoulos

3

0 references

Olga Touloumi

4

0 references

David Rosenmann

5

0 references

Oded Abramsky

6

0 references

Hanna Rosenmann

Journal of Neuropathology & Experimental Neurology

7

0 references

language of work or name

English

0 references

publication date

March 2009

0 references

published in

0 references

volume

68

0 references

issue

3

0 references

page(s)

314-25

0 references

cites work

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Impact of HMG-CoA reductase inhibition on brain pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Basophilia, acidophilia and argyrophilia of "dark" (compacted) neurons during their formation, recovery or death in an otherwise undamaged environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Microglia as a potential bridge between the amyloid beta-peptide and tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Lovastatin modulation of microglial activation via suppression of functional CD40 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Effects of statins on microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Simvastatin enhances learning and memory independent of amyloid load in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB

Statin Use and the Risk of Incident Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0B013E31819AC3CB